Physician profile
John Shapiro
NPI 1790704179
$4,523.18
in general payments reported to CMS, 2019-2025
35 companies · $27.66 in 2025
The $27.66 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $835 · 2020: $393 · 2021: $187 · 2022: $968 · 2023: $2,037 · 2024: $74.90 · 2025: $27.66.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,131 · Education: $9.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,130.86 |
| Education | $9.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $817.21 | 2019-2024 | Trelegy Ellipta, Arexvy, Nucala |
| Astrazeneca Pharmaceuticals LP | $455.86 | 2019-2023 | Fasenra, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $430.12 | 2019-2023 | Ofev |
| Regeneron Healthcare Solutions, INC. | $291.56 | 2019-2023 | Dupixent |
| Genzyme Corporation | $256.63 | 2019-2023 | |
| Mylan Specialty L.P. | $220.85 | 2019-2023 | Yupelri |
| Actelion Pharmaceuticals US, INC. | $205.17 | 2019-2023 | Opsumit, Uptravi |
| United Therapeutics Corporation | $167.51 | 2020-2023 | Tyvaso |
| Insmed, INC. | $149.73 | 2019-2024 | Arikayce |
| Grifols USA, LLC | $144.76 | 2022-2023 | Prolastin-C Liquid |
| Mallinckrodt Hospital Products INC. | $140.19 | 2022-2023 | Acthar |
| Bayer Healthcare Pharmaceuticals INC. | $137.76 | 2020-2023 | |
| Harmony Biosciences LLC | $127.36 | 2021-2023 | Wakix |
| Axsome Therapeutics, INC. | $116.84 | 2023 | Sunosi |
| Takeda Pharmaceuticals U.S.A., INC. | $115.99 | 2023 | Glassia |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $99.02 | 2019-2020 | |
| Ambu INC. | $72.98 | 2022 | |
| Alexion Pharmaceuticals, INC. | $70.94 | 2022-2023 | Ultomiris |
| Genentech USA, INC. | $67.19 | 2019-2023 | Xolair |
| Amgen INC. | $61.67 | 2022-2023 | Tezspire |
| Inspire Medical Systems, INC. | $45.76 | 2023-2025 | Inspire |
| Merck Sharp & Dohme LLC | $33.41 | 2023 | Zerbaxa, Recarbrio |
| Shire North American Group INC | $33.18 | 2019 | |
| Jazz Pharmaceuticals INC. | $31.33 | 2019-2023 | Xywav |
| Csl Behring | $30.68 | 2019 | |
| Mallinckrodt Enterprises LLC | $30.51 | 2019 | |
| Novartis Pharmaceuticals Corporation | $26.68 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $25.97 | 2022 | |
| Baxter Healthcare | $21.17 | 2023 | Hillrom - Life 2000 Ventilation System |
| Avadel Cns Pharmaceuticals, LLC | $19.29 | 2023 | Lumryz |
| Ani Pharmaceuticals, INC. | $18.85 | 2022 | |
| Vanda Pharmaceuticals INC. | $18.82 | 2019 | |
| Abbvie INC. | $15.79 | 2021 | |
| Janssen Pharmaceuticals, INC | $11.40 | 2019 | |
| Philips North America LLC | $11.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Shapiro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.